Over 700 Calgarians go for a Dog Jog to support Humane Society
North Glenmore Park was full of hundreds of dogs and dog lovers Saturday, who showed up to support the Calgary Humane Society at its 24th annual Dog Jog.
The event raised over $200,000 for the Humane Society, said vice executive director Brad Nichols.
'It's really one of our signature fundraisers for humane society in general, and it's been centered around the mandate of ending animal cruelty at this point," said Nichols.
'We don't receive any government funding whatsoever,' he added. 'So, you know, (it's) difficult to run a complex department like that on zero government dollars, but we managed to make it happen because of the strong support that we get from Calgary.'
Dog lover Richard Preece was there with his family.
'We used to come years ago with me and my wife, and we just haven't come out since we had kids, and we thought they were old enough to come to their first one,' he said.
'We have another dog we adopted from Humane Society, and have always thought they were good organization. And, you know, it's just a lot of fun -- and it's good for the dogs.'
Sharlene Elford was there, too, with her daughter Brook and her dog Gus.
'We wanted to raise awareness for animal cruelty and participate in get outdoors and exercise,' Sharlene said.
'Seeing all the different types of dogs is really cool. There's a lot of dogs here.'
For more information about the Calgary Humane Society, go here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
15 minutes ago
- CTV News
Raising awareness for invasive species
Atlantic Watch The head gardener from the Fredericton Botanic Garden discusses an upcoming invasive species workshop.
CTV News
15 minutes ago
- CTV News
WATCH: Gas line break and fire close section of Ottawa Street in Windsor
A section of Ottawa Street in Windsor is closed for a fire and a gas line break. A section of Ottawa Street is closed Thursday morning as crews battle a fire and a gas line break at the back of a building. One neighbour in the area told CTV News she was awoken by the fire around 4:45 a.m. There is no word on how the fire started. Ottawa Street is closed between Langlois Avenue and Hall Avenue. People are being asked to avoid the area.
National Post
an hour ago
- National Post
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Article content BOSTON & SCCT ANNUAL MEETING, MONTREAL — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors. Article content These appointments will help guide Elucid as it accelerates its clinical research strategy, commercializes its flagship PlaqueIQ TM coronary plaque assessment technology, and continues development of its investigational FFR prediction model, based on PlaqueIQ. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. Article content An experienced medical technology executive and clinical expert, Dr. Kuntz is former senior vice president and chief medical and scientific officer of Medtronic plc. Prior to joining Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization that coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration (FDA). Dr. Kuntz has directed several multicenter clinical trials and has authored more than 250 original publications. Dr. Kuntz was an associate professor of Medicine at Harvard Medical School, chief of the division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston. Article content Dr. Feinglass is a managing director at Manatt Health working across the business, medical, and policy needs of health systems, life sciences, medical device, digital health and diagnostic companies globally. A global leader in health care, Dr. Feinglass has served as an executive and chief medical officer in large multi-national life sciences corporations including Danaher and Zimmer-Biomet. In parallel, she has driven policy changes alongside senior government officials around the world to influence health policy, regulation, and access. A former regulator at U.S. Centers for Medicare and Medicaid Services (CMS) and commander in the U.S. Public Health Service with extensive regulatory and legislative experience, Dr. Feinglass is on faculty at the John's Hopkins Bloomberg School of Public Health, Department of Mental Health and is a member of the Board of Directors of Sandoz AG. Article content 'We are honored that Dr. Richard E. Kuntz and Dr. Shamiram Feinglass have joined Elucid's Board of Directors,' said Elucid CEO Kelly Huang, PhD. 'Rick lends an important and experienced interventional cardiology view, as well as expertise in clinical trial strategy and execution, and product innovation strategy. Coupled with Shami's unparalleled expertise in market access, policy making, and regulatory strategy, the two will be invaluable as we push forward our vision of a future where cardiac care is personalized, precision patient care versus risk factor and population-based care.' Article content About Elucid Article content Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Sam Choinski Article content Article content Article content Article content
